PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Paris:BIO) announces that it has just received the following press release from Immtech Pharmaceuticals, Inc. , the US company from which it has licensed the European rights for pafuramidine: NEW YORK, Dec. 26 -- Immtech Pharmaceuticals, Inc. (The Company
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck Sharp & Dohme (MSD) announced today that ISENTRESS(reg) (raltegravir) has been granted a license from the European Union Commission (Commission) by way of a decision for use in combination with other antiretroviral medicinal products for the treatment of HIV-1 infect
New Genotyping Console(TM) 2.0 Offers up to 10 Times the Sensitivity for Detecting Copy Number Changes Than Competing Platforms SANTA CLARA, Calif. -- Affymetrix Inc. (Nasdaq:AFFX) today announced the availability of its Genotyping Console(TM) 2.0 (GTC 2.0) Software, an easy-to-use analysis tool for determining single
WEST PALM BEACH, Fla. -- The widespread use of anabolic steroids by pro baseball players that was revealed in former Senator George Mitchell s bombshell report begs the question of role models and player s influence on young athletes. Many teenagers don t know the risks of performance enhancing drugs, but do understand
Product Developed Through Joint Venture Between Bristol-Myers Squibb and Gilead Sciences , the First of Its Kind in HIV Treatment PRINCETON, N.J. & FOSTER CITY, Calif. -- The European Commission has granted marketing authorization for ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/
WASHINGTON -- Oval Office, 10:50 A.M. EST PRESIDENT BUSH: Mr. President, it s been my honor to welcome you here to the White House. We just had a very extensive and fruitful discussion on a variety of issues, and that s what you would expect when friends meet together. The President is committed to democracy and rule o
MINNEAPOLIS--(BUSINESS WIRE)--Public Radio International (PRI) announces that it has received a three-year, $5 million grant from the Bill & Melinda Gates Foundation to lead an unprecedented effort to produce and distribute global health and development content. By creating an array of penetrating journalism for us
INDIANAPOLIS -- Interactive Intelligence (Nasdaq:ININ) CEO, Dr. Donald E. Brown, has donated $1 million in stock to the Indiana University- Kenya Partnership, a program designed to prevent and treat HIV/AIDS. This is the single largest private donation since the program s inception. The Partnership began in 1989 whe
PRINCETON, N.J. & FOSTER CITY, Calif. -- Bristol-Myers Squibb Company (NYSE:BMY) and Gilead Sciences , Inc. (Nasdaq:GILD) today announced an agreement to commercialize ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) in Europe for the treatment of
LOUISVILLE, Ky. -- Humana Inc. (NYSE: HUM) announced today that it has signed multi-year agreements with Laboratory Corporation of America(R) Holdings (NYSE: LH) and Quest Diagnostics (NYSE: DGX), extending current contracts that provide laboratory and testing services for Humana members. The agreements are effective J
WATERTOWN, Mass. -- Panacos Pharmaceuticals, Inc. (NASDAQ:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced preliminary results from the 350 mg cohort of a Phase 2b study of bevirimat (PA-457) in patients failing HIV therapy due to drug resista
MORRISVILLE, N.C. -- Trimeris, Inc. (NASDAQ: TRMS) today announced its strategic plan for 2008 that is designed to maximize cash flows from FUZEON while also advancing TRI-1144 to a value-creating milestone. The Company plans to file an Investigational New Drug application ( IND ) for TRI-1144, the Company s next-gener
WINSTON-SALEM, N.C. -- Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics (TM), today announced that it has initiated a Phase I clinical trial of its product candidate TC-6499. The initiation of the trial triggers a $6.0 million milestone
PARIS -- Cookshow.com, the first 100% video-sharing community exclusively on the niche of cooking, announced today that it has formed a strategic partnership with the corporate giving program of Project Concern International (www.projectconcern.org). The company will donate a fixed amount of (euros)10 ($14) for each re
WASHINGTON -- James S. Brady Press Briefing Room 12:30 P.M. EST MS. PERINO: Hi, everybody. Just a quick comment. The President, as you know, at 1:40 p.m., is going to make a statement after getting a briefing from Secretaries Paulson and Jackson on housing. In August, the President proposed legislative reforms to assis
SUNNYVALE, Calif.--(BUSINESS WIRE)--ARK Diagnostics, Inc. ( ARK ), and Roche Diagnostics signed a letter of intent to negotiate a collaboration agreement that would grant Roche distribution and commercialization rights for ARK s anti-HIV drug monitoring products. We are pleased to partner with Roche Diagnostics - a wor
iClips uses Swarmcast Live to stream high-quality video to global audience MINNEAPOLIS--(BUSINESS WIRE)--Swarmcast, the leader in high-quality online video delivery, and iClips.net, the leading provider of free online concert streams, recently teamed together to provide a live Internet broadcast from Nelson Mandela s 4
Building a Consistent Product Portfolio in Opportunistic Infections in Cancer And AIDS Patients BioAlliance Pharma to Host a Conference Call Today At 11.30 AM CET Paris Time (10.30 AM GMT, London Time) PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Euronext Paris - ticker code BIO), today announced tha
LAUSANNE, Switzerland--(BUSINESS WIRE)--The Swiss Institute for Vaccine Research will be launched on December 5, 2007, in Lausanne, Switzerland. The new Institute will encompass the principal aspects of vaccine research to fight the three main infectious diseases: HIV/AIDS, tuberculosis and malaria. The Institute will
James Blunt, Kate Bosworth, Ray Winstone, Christian Slater and Nelson Mandela s HIV/AIDS charity, 46664, Support New Online Network LOS ANGELES & LONDON--(BUSINESS WIRE)--t5m today announced the first socially-conscious, online TV network, whose mission is to inspire and entertain - www.t5m.com. t5m gives users dir
Canopus President Speaks Among Presidential Candidate and New York Senator Hillary Clinton and Other World and Industry Leaders Global Summit on AIDS and the Church LOS ANGELES--(BUSINESS WIRE)--Canopus BioPharma, Inc. (OTCPK:CBIA), a biotechnology company developing pharmaceutical products and assay methods for patien
PORTLAND, Ore.--(Business Wire)--Calypte Biomedical Corporation (OTCBB: CBMC), a developer, manufacturer and marketer of HIV diagnostic tests, announced today that, in honor of World AIDS Day, it has donated 4,000 Aware(TM) HIV-1/2 OMT (oral fluid) tests to the National AIDS Control Council (NACC) of the Republic of
More than 900 Employees Volunteer to Raise Funds in NJ --(BUSINESS WIRE)--Roche WHAT: Opportunity to speak with NJ patients and volunteers. More than 900 local Roche employees have volunteered to participate in the fifth annual Global Roche Employee AIDS Walk today to raise funds to support children infected and affect
WASHINGTON--(BUSINESS WIRE)--James S. Brady Briefing Room 1:40 P.M. EST MS. PERINO: It s been our great pleasure to work with Kelly O Donnell of NBC News. And today is her last day covering the White House full-time, and so we wish you the very best in your -- (applause.) MS. O DONNELL: Thank you. MS. PERINO: Maybe you
Online TV network to deliver behind-the-scenes coverage of World Aids Day Concert, featuring artists Peter Gabriel, Annie Lennox, Corinne Bailey Rae, Razorlight, Ludacris, Goo Goo Dolls and Jamelia CAPE TOWN, South africa & LOS ANGELES & LONDON--(BUSINESS WIRE)--t5m.com, the first socially-conscious online TV n
--(BUSINESS WIRE)--Office AIDS Programs and Policy: WHAT: The County of Los Angeles, Department of Public Health, Office of AIDS Programs and Policy, will recognize government officials, public health leaders and HIV/AIDS community representatives in an awards ceremony and breakfast commemoration of World AIDS Day on D
City of West Hollywood: WHAT: On World AIDS Day, Saturday, December 1, 2007, the City of West Hollywood will once again sponsor and originate AIDSWATCH, an electronic, televised memorial. AIDSWATCH is in its 11th year. For 24 hours beginning at midnight, West Hollywood Citychannel 10 (on Time Warner Cable) will display
WASHINGTON -- Office of the Press Secretary - World AIDS Day 2007 Today, President and Mrs. Bush will mark World AIDS Day 2007 by participating in a faith-based roundtable discussion at Calvary United Methodist Church in Mount Airy, Maryland. Since 2001, the Administration has delivered more than $129 billion to fight
MELBOURNE, Australia -- Biotechnology company Avexa Limited (ASX:AVX) announced today that a series of in-vitro experiments have shown that ATC maintains potent antiviral activity against strains of HIV which are resistant to the new class of integrase inhibitors, including the recently approved Merck HIV integrase inh
PASADENA, Calif. -- Kaiser Permanente recently announced more than $1.3 million in statewide community benefit grants to help 74 organizations promote HIV/AIDS awareness, prevention, screening, support and treatment for people living with the disease. The individual grants were made throughout 2007 and were given to no
Florida State University Head Coach Bobby Bowden and University of Miami Head Coach Randy Shannon Join Forces to Support Through Their Eyes Photographic Exhibit Created by Young Adults Born with HIV/AIDS Florida Department of Health Partners with FSU and the Green Family Health Initiative at University of Miami to Tran
MOUNT AIRY, Md. -- Calvary United Methodist Church 11:43 A.M. EST THE PRESIDENT: Tomorrow is World AIDS Day, and Laura and I are honored to commemorate the occasion here at the Calvary United Methodist Church. And we re honored to commemorate the day with people who have dedicated their lives to save lives. I want to
BETHLEHEM, Pa. -- OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, today announced its support of more than 150 global and domestic rapid HIV testing initiatives in recognition of World AIDS Day, commemorated annually on December 1st. OraSure s support of these initiatives, taking
ATLANTA -- Inhibitex, Inc. (Nasdaq: INHX) today announced it has established a new scientific advisory board to provide the Company with scientific and clinical guidance on its ongoing research and development activities. The Company s scientific advisory board is composed of distinguished scientists and thought leader
MINNEAPOLIS -- The Minnesota AIDS Project announced today that it will kick off a new campaign to recognize important stories and leaders in the last 25 years of fighting HIV in Minnesota. The campaign, titled 25 Years/25 Stories, will launch on World AIDS Day 2007 (December 1) with the story of the first case of HIV i
MONTEREY, Calif. -- In observance of World AIDS Day (December 1, 2007), Language Line Services, the leading provider of language solutions, has announced the introduction of the Relating in Red AIDS awareness dual-handset phone program. As part of this fundraising program for HIV/AIDS awareness, health care providers w
PARIS -- Regulatory News: BioAlliance Pharma SA (Paris:BIO) today announced it has extended its ongoing acyclovir Lauriad(R) Phase III trial in the treatment of oral herpes to the United States . Ten clinical centers have been opened in the country and will join the forty or so in Australi
OAKLAND, Calif. -- MOTIVATE -- a global partnership between Ramsell and Sojitz -- and the Ministry of Health of the Socialist Republic of Vietnam , AIDS Committee Ho Chi Minh City sign a Memorandum of Understanding (MOU) setting up the fundamental principles for the collaboration between the AIDS Committee Ho Chi Minh
SAN DIEGO -- Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today that its partner, Tripep AB of Sweden , treated the first subject in a Phase I/II clinical trial of a novel DNA vaccine designed to treat chronically infe
MELVILLE, N.Y. -- Allion Healthcare, Inc. (NASDAQ: ALLI), a national provider of specialty pharmacy and disease management services focused on HIV/AIDS patients, announced today it will participate in the Piper Jaffray 19th Annual Health Care Conference in New York City at the The Pierre hotel, November 27th through No
OKLAHOMA CITY -- Production of TUBERCIN™, a revolutionary polysaccharide compound to be used as an HIV/AIDS and ANTI-CANCER immunostimulant, has begun with the focus on South Africa and the Bahamas as mission delivery sites, announces Mr. Gerry Knight, Executive Vice President of ARTEC, Inc.™ (Pink Sheets:ATKJ).
PHILADELPHIA -- The Penn Libraries, in partnership with the University of Pennsylvania s Lesbian Gay Bisexual Transgender Center, and other campus agencies, will commemorate the 20th anniversary of the AIDS Memorial Quilt, internationally recognized as a symbol of personal and universal grief, remembrance, and healing
MELBOURNE, Australia -- Avexa (ASX:AVX) announced at its Annual General Meeting (AGM) today that it has received positive feedback from both North American and European regulatory authorities allowing immediate progression into a Phase III program for apricitabine (ATC), an NRTi the company is developing for the treatm
LOS ANGELES -- FATHER MICHAEL S LOTTERY: A NOVEL OF AFRICA by Johan Steyn, a debut novel concerning the AIDS crisis in Southern Africa, has just been named a Booksense Notable for January 2008, according to the publisher Schaffner Press, Inc. of Tucson, Az. The Booksense endorsement is the latest accolade bestowed upon
LOS ANGELES -- African Red Tea Imports (ART) is pleased to announce the addition of two major new products to their outstanding line of Rooibos based organic and kosher products. Sutherlandia Frutescens, known in South Africa as Cancer Bush, and Sceletium Tortuosum, a plant with recorded usage dating back to the 1600s,
SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD), a pioneer in developing medical devices to treat infectious disease, announced today that researchers have documented the Aethlon Hemopurifier(R) is able to remove the immunosuppressive activity normally found in the fluid of cancer patients. Aethlon recently discovered
BOCA RATON, Fla. -- Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis(MS), has today announced that its wholly owned subsidiary, Designer Diagnostics, Inc., will be featured in an upcoming article published in the International Journal of TB and Lung Diseas
PARIS -- Regulatory News: BioAlliance Pharma SA (Paris:BIO), today announced that it had successfully completed patient enrolment in the pivotal phase III clinical trial performed with a view to registering Loramyc(R) in the US, for the treatment of oropharyngeal candidiasis. With 540 patients enrolled by 40 specialist
DUBLIN, Ireland--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/reports/c74552) has announced the addition of Stakeholder Insight: HIV Therapy Dynamics to their offering. Introduction Despite several developments in efforts to tackle the spread of HIV, the total number of people living with HI
SAN DIEGO -- Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced that Dr. Michael Fons, Vice President, Corporate Development, has been invited to present an overview of the company s technology and products at the 2007 Annua
SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD), a pioneer in developing medical devices to treat infectious disease, announced today it has initiated a research collaboration to study the in vitro effectiveness of the Aethlon Hemopurifier(R) to clear the Human Immunodeficiency Virus (HIV) from blood. The studies are b
SEATTLE -- Merck & Co. , Inc. and the HIV Vaccine Trials Network (HVTN) today announced that study volunteers in the STEP study of Merck s HIV vaccine (V520) will be told whether they received vaccine or placebo, and all study volunteers will be encouraged to continue to return to their study sites on a regular bas
CHICAGO -- UnBuenDoctor(R) has launched the first Spanish-language website that will focus on the 32.2 million Spanish speakers in the US and allow them to search for doctors and organizations while obtaining the latest information about their health, beauty, nutrition and diverse well-being issues that prevail through
The Natixis Securities MidCap Healthcare Conference PARIS, France Regulatory News: BioAlliance Pharma SA (Paris:BIO), a specialty pharmaceutical company focused on the development and marketing of innovative therapeutics which address resistance issues in cancer, HIV and opportunistic infections, today announced that i
SAN DIEGO -- In response to the lack of knowledge regarding cross-border health, the International Community Foundation and Fundacion International de la Comunidad A.C. are providing an educational documentary to help inform San Diegans about critical health issues affecting both sides of the border. San Diegans are fa
NEW YORK & CAPE TOWN, South Africa -- The Global Alliance for TB Drug Development (TB Alliance), a not-for-profit, product development partnership accelerating the discovery and development of new drugs to fight tuberculosis (TB), today announced the advancement of two promising TB treatment candidates into the nex
38th Union World Conference on Lung Health BOCA RATON, Fla. -- Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis (MS), has today announced that leading NonTuberculous Mycobacterium (NTM) research scientist, Dr. Rahul Narang, will be showcasing the Designer
SEATTLE -- In the STEP study, one of two phase II trials of Merck & Co. , Inc. s investigational HIV vaccine (V520), the vaccine was not effective at either preventing infection in volunteers not previously infected with HIV or at reducing viral loads in those study volunteers who became infected with HIV during th
SAN DIEGO -- JHG-Townsend, a results-driven communications group that effectively combines traditional marketing and PR services with new digital media, today announced it has been named as a finalist in the Event PR category for PR News prestigious Non-Profit PR Awards. The public relations campaign was designed to la
SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD), a pioneer in developing medical devices to treat infectious disease, disclosed today that its Chairman and CEO, James A. Joyce, will be presented the Spirit of India award at the America India Foundation (AIF) annual gala on December 1, 2007. The event, sponsored by the
ATLANTA -- Metastatix, Inc., an emerging pharmaceutical company focused on the development of small molecule therapeutics, announced today that the U.S. Food and Drug Administration ( FDA ) has accepted its Investigational New Drug (IND) application for MSX-122, a potent CXCR4 inhibitor that the company is developing f
SEATTLE -- The Institute for Systems Biology announces that Bill Gates, co-chair of the Bill & Melinda Gates Foundation and chairman of Microsoft Corporation and Nathan Myhrvold, PhD, president and CEO of Intellectual Ventures, will serve as keynote speakers for the 7th Annual Institute for Systems Biology Internat
Key Highlights of Aurum Agreement: * Guardian s Signature Mapping technology to potentially save thousands of lives with early detection of TB bacteria and Malaria parasites * Guardian to raise visibility in worldwide healthcare community * Aurum to provide access to critical expertise and clinical case studies for tar
LA JOLLA, Calif.--(BUSINESS WIRE)--Instead Inc., developer of over-the-counter women s reproductive health products, has patented a new reusable showerhead vaginal applicator, which it plans to distribute with its FDA-cleared personal vaginal lubricant and candidate microbicide, Amphora. Designed to be more comfortable
BOSTON -- Gilead Sciences , Inc. (Nasdaq:GILD) today announced the presentation of detailed 48-week data from two phase III pivotal clinical trials, Studies 102 and 103, which evaluate the safety and efficacy of once-daily Viread (R) ( tenofovir disoproxil
SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD), a pioneer in developing medical devices to treat infectious disease, announced today that it has initiated clinical testing the Aethlon Hemopurifier(R) in human studies being conducted at the Fortis Hospital in Delhi, India . The study, approved by the Ethics Committee f
BIOCOM 2007 SAN DIEGO -- Aethlon Medical, Inc., (OTCBB:AEMD) a pioneer in developing medical devices to treat infectious disease, is scheduled to give a presentation this Friday, November 2nd at the BIOCOM Investor Conference 2007. Aethlon Chairman and CEO, James A. Joyce will provide an overview of the company, includ
SAN DIEGO -- Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today that its partner, Tripep AB of Sweden , has begun enrolling patients for its Phase I/II clinical study of a novel DNA vaccine designed to treat chronicall
WATERTOWN, Mass. -- Panacos Pharmaceuticals, Inc. (NASDAQ:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, will present at the CIBC World Markets 18th Annual Healthcare Conference to be held from November 5-7, 2007 at the Waldorf-Astoria Hotel in New York, NY
11th European AIDS Conference (EACS) FOSTER CITY, Calif. -- Gilead Sciences , Inc. (Nasdaq:GILD) today announced 48-week data from a Phase III clinical trial evaluating virologically-suppressed patients with HIV who switched from treatment with twice-daily Combivir (R) (lamivudine/z
City of West Hollywood: WHAT: The City of West Hollywood, recording artists HANSON and TOMS Shoes will join together to help fight poverty and HIV/AIDS in Africa. The partnership is a component of the City s Global AIDS Initiative which was created with the goal of advocating for and supporting education, outreach and
WEST HOLLYWOOD, Calif. -- The heart of West Hollywood, Santa Monica Boulevard, will once again be pulsing with excitement on Halloween night as hundreds of thousands of Halloween revelers are expected to flock to the famous Boulevard for the 2007 West Hollywood Halloween Costume Carnaval on Wednesday, October 31, 2007
NUTLEY, N.J. -- Final 48-week results from an international head-to-head trial, presented today at the 11th European AIDS Conference (EACS), Madrid, demonstrated that treatment-naive HIV patients treated with the protease inhibitor Invirase (R) 500mg tablets (saquinavir mesylate), boosted with
-- Long-Term Data and Integrated Subgroup Analysis in Patients with Idiopathic PAH and PAH Associated with Connective Tissue Disease Presented at the Annual Meeting of the American College of Chest Physicians -- CHICAGO -- Gilead Sciences , Inc. (Nasdaq: GILD) today announced the presentation of new data from the Phase
KELOWNA, British Columbia -- YourTechOnline.com Inc, PC Magazine Editors Choice award-winning provider of 24-hour-a-day online technical support, announces its plan to bring technical support and infrastructure advancement to the HIV/AIDS relief and child education crisis in Africa. The first organizations to be suppor
MONROVIA, Calif. -- Prolacta Bioscience, a privately held company that offers the first and only milk fortifier made from 100% human milk for the nutritional needs of premature and critically ill infants, announced the donated processing of over 50,000 ounces of milk for the International Breast Milk Project (IBMP). Th
WEST HOLLYWOOD, Calif. -- The City of West Hollywood, recording artists HANSON and TOMS Shoes will join together to help fight poverty and HIV/AIDS in Africa. The partnership is a component of the City s Global AIDS Initiative which was created with the goal of advocating for and supporting education, outreach and fund
GAITHERSBURG, Md. -- GenVec, Inc. (Nasdaq:GNVC) announced today that the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has executed its sixth option period (year seven) under its multi-year collaboration with GenVec t
WASHINGTON -- Hilton Washington Washington, D.C. October 18, 2007 8:57 P.M. EDT MRS. BUSH: Thank you, Charlayne. Thank you, everyone. Thank you very, very much, Charlayne. Her Excellency, Ellen Johnson-Sirleaf, President of Liberia , it s great to have this opportunity to be with you. I m thrilled to have the chance to
PRINCETON, N.J. & FOSTER CITY, Calif. & WHITEHOUSE STATION, N.J. -- Bristol-Myers Squibb Company (NYSE:BMY), Gilead Sciences , Inc. (Nasdaq:GILD) and Merck & Co. , Inc. (NYSE:MRK) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issue
PRINCETON, N.J. & FOSTER CITY, Calif. -- Bristol-Myers Squibb Company (NYSE:BMY) and Gilead Sciences , Inc. (Nasdaq:GILD) announced today that Health Canada has approved ATRIPLA(R) ( efavirenz 600 mg/emtricitabine 200 mg/
LOS ANGELES -- U.S. Doctors for Africa (USDFA) (www.usdfa.org) announces the Ghana Mobile Clinic Project-the deployment of its first mobile clinic to Africa. This is the first clinic of an anticipated 200 mobile clinics USDFA has committed to deploy by 2015 as part of its Mobile Clinic Initiative, a commitment made by
EAST HILLS, N.Y. -- Experts called on government and medical organizations involved in blood transfusion to reverse one of the most serious public health policy errors in the history of transfusion therapy in the United States . Neil Blumberg, M.D. and Joanna M. Heal, M.D., specialists in transfusion medicine and hemat
Test for Life: WHO: Congresswoman Ileana Ros-Lehtinen to take HIV test to mark National Latino AIDS Awareness Day Panel Members: -- Alberto Santana: Office of HIV/AIDS/TB, Miami-Dade County Health Department -- Manuel Laureano-Vega M.S.,M.D.: Founder and Executive Director of Liga Contra Sida -- Maria G. Rodriguez, MD,
NEW YORK & LOS ANGELES -- IndieMV Media Group Inc. and associated Companies (Jake s Trucking International Inc. (OTCBB:JKTI)) announced today the official launch of the Company s web property www.IndieMV.com and shared details about their recent partnership with UNICEF to provide music-video based contests surround
WHITEHOUSE STATION, N.J. -- Merck & Co. , Inc., announced Friday that the U.S. Food and Drug Administration ( FDA ) granted ISENTRESS(TM) (raltegravir) tablets accelerated approval for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-experienced adult patients wh
MIAMI -- President Bush will welcome President Yoweri Museveni of the Republic of Uganda to the White House on October 30, 2007. The President and President Museveni will discuss Uganda s leadership in Somalia , the Lord s Resistance Army, and President Museveni s development plan for northern Uganda, as well as their
FOSTER CITY, Calif. -- Gilead Sciences , Inc. (Nasdaq: GILD) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration ( FDA ) and a Type II variation to the European Medicines Agency (EMEA) for marketing approval of
BETHLEHEM, Pa. -- OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, today announced the launch of a Rapid HIV Testing Initiative in connection with National Latino Awareness Day 2007. This Initiative is being conducted in partnership with the Latino Commission on AIDS with support f
OAKLAND, Calif. -- Sexually transmitted diseases (STDs), largely unreported, are costing California more than a billion dollars a year, according to a study published in the California Journal of Health Promotion. Researchers at the Public Health Institute s (PHI) Center for Research on Adolescent Health and Developmen
Inovio anticipates human data from first-in-man studies using its electroporation-mediated DNA delivery technology, adding to interim data that provided initial validation of the technology s ability to deliver and enhance potency of DNA-based immunotherapies Inovio has ample cash as it contracts the SECTA program and
MENLO PARK, Calif. -- Geron Corporation (Nasdaq:GERN) today announced that Alan B. Colowick, Ph.D., M.P.H., president, oncology, will present an update of the company s oncology programs at 10:45 a.m. PDT on Wednesday, Oct. 10, 2007, at the Biotechnology Industry Organization Investor Forum in San Francisco. The update
LOS ANGELES -- Canopus BioPharma, Inc. (OTC: CBIA), a biotechnology company developing pharmaceutical products and assay methods for patients suffering from infectious disease, radiation sickness, cancer, and addiction, announced today the commencement of a 30 patient Phase II clinical trial for its new HIV-1 anti-vira
SAN DIEGO -- CANCIDAS(R) (caspofungin acetate), given once daily, was evaluated as a treatment for patients three months to 17 years of age with documented or suspected fungal infections. The use of CANCIDAS in pediatric patients is investigational. Interim results from the first Phase II clinical trial to study this t
NUTLEY, N.J. & MORRISVILLE, N.C. -- Roche and Trimeris, Inc. (Nasdaq: TRMS) today provided an update on our efforts to offer a needle-free device which has been investigated for use with FUZEON(R) ( enfuvirtide ). Based on comprehensive assessment of the clinical program, as well a significant delay in achieving U.
PORTLAND, Ore. -- Bioject Medical Technologies Inc. (Nasdaq:BJCT), a leading developer of needle-free drug delivery systems today announced that it has been notified by Roche and Trimeris that they will not be proceeding with their FDA submission for Fuzeon(R) to be administered with the Biojector(R) 2000 ( B2000 ).
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c70369) has announced the addition of Encyclopaedia of Infectious Diseases: Modern Methodologies to their offering This book was developed out of the understanding that advances in infectious disease research are dependent upon the devel
GAITHERSBURG, Md. -- GenVec, Inc. (Nasdaq: GNVC) announced today that the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), has executed its first option period (year two) under a previously announced five-year, $52 million contract with GenVec for the produc
GENEVA, Switzerland -- European Risk Managers attending the FERMA (Federation of European Risk Managers) Congress in Geneva have helped ACE European Group (ACE)(NYSE:ACE) to raise over $40,000 (30,000 euros) for a Red Cross HIV/ AIDS educational programme in India . ACE Foundation- International con
NEW YORK -- On October 12, the PBS weekly newsmagazine, NOW, travels around the world for a revealing exploration of forced child marriage in developing countries, and how people can act locally and globally to solve the problem. An estimated 100 million girls will be married over the next 10 years, and the hour-long s
SAN DIEGO -- Ichor Medical Systems, whose advanced electroporation system is being tested worldwide for its ability to increase the effectiveness of DNA drugs and vaccines, has entered into an agreement with two distinguished research organizations to test a promising HIV vaccine, ADVAX, in human volunteers. Under the
DURHAM, N.C. -- Argos Therapeutics today announced that Ralph Steinman, M.D., a scientific founder of the Company, has received the 2007 Albert Lasker Award for Basic Medical Research for his discovery of dendritic cells. Dendritic cells are a key element of the immune system, responsible for initiating and stimulating
(Editors: B-roll footage is available at http://streaming.uclahealth.org/researchbuilding2. Please note that you will need Windows Media to open the video.) LOS ANGELES -- The UCLA Biomedical Sciences Research Building and Orthopaedic Hospital Research Center, an exciting new research hub located on the UCLA campus, wa
SANTA CLARA, Calif. -- Former President Bill Clinton announced today at the Clinton Global Initiative (CGI) in New York that Intel Corporation will bring its landmark teacher training program online to help more than 1.5 million teachers in 15 countries learn how to best integrate technology into their lesson plans to
PARIS -- Cytheris, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced expansion of the clinical trial program for CYT107, the company s recombinant human Interleukin-7 (IL-7), with the initiation of a Phase I/IIa clinical trial in HIV p
NEW YORK -- The Pierpont Morgan Library and Museum 12:17 P.M. EDT MRS. BUSH: Thank you very much, Dr. Rice. Thank you all. Thanks so much. Thank you, Dr. Rice, for that very kind introduction. And I want to say a special welcome to Mrs. Ban. Thank you so much for welcoming all of us here for the United Nations General
NEW YORK -- Pfizer Inc announced today that the European Commission (EC) has approved Celsentri(R) (maraviroc). Treatment-experienced HIV patients in the EU can soon benefit from the first CCR5 antagonist and only oral entry inhibitor. Maraviroc, in combination with other antiretroviral medicinal products, is indicated
LOS ANGELES -- Today, (RED), the initiative launched last year to engage corporate and consumer power in the fight against AIDS in Africa, announced that the sales of (PRODUCT) RED-branded products had generated more than $45 million for the Global Fund (www.theglobalfund.org). In 2006, (RED) set out to create a sustai
OKLAHOMA CITY -- ARTEC, Inc., (Pink Sheets: ATKJ), visionary pharmaceutical firm, has acquired the preliminary outline to be used for the testing protocol from a sponsoring scientific group in South Africa for TUBERCINTM, a revolutionary polysaccharide compound to be used as an HIV/AIDS and ANTI-CANCER immunostimulant.
WHITEHOUSE STATION, N.J. & SEATTLE -- Vaccination in a phase II clinical trial of Merck & Co. , Inc. s investigational HIV vaccine (V520) is being discontinued because the vaccine was not effective. The announcement was made today by the co-sponsors of this clinical trial, Merck & Co., Inc., and the HIV Vac
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c69049) has announced the addition of Peripheral Neuropathy and Neuropathic Pain, 2007 to their offering. Current, pipeline and emerging drugs for the treatment of peripheral neuropathy
WATERTOWN, Mass. -- Panacos Pharmaceuticals, Inc. (NASDAQ:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, will present at the UBS Global Life Sciences Conference to be held from September 24-27, 2007 at The Grand Hyatt in New York, NY. Dr. Alan W. Dunton, Pa
CAMP HILL, Pa. -- Nearly 1,700 Rite Aid (NYSE:RAD) pharmacies will offer a one-day flu clinic on October 16, 17 or 18 to help patients stay healthy this season. Patients can receive a flu shot as well as a coupon book for items throughout the store valued at more than $230. Flu shots are free of charge for patients wit
PORTLAND, Ore. -- Calypte Biomedical Corporation (OTCBB: CBMC), a manufacturer of medical diagnostic tests for the rapid detection of antibodies to the human immunodeficiency virus (HIV), announced today that its Aware(R) HIV-1/2 OMT oral fluid rapid test has been approved by the U.S. Agency for International Developme
WILMINGTON, Del. -- Incyte Corporation (Nasdaq:INCY) announced today that four scientific posters have been presented at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) that is being held in Chicago, Illinois. INCB9471 is a novel, orally available CCR5 antagonist that is a membe
SAN FRANCISCO -- Presidio Pharmaceuticals, Inc. announces today that internationally recognized virologist and antiviral drug discoverer Dr. Richard Colonno has joined the company as Chief Scientific Officer. Rich brings to Presidio over 25 years of experience in antiviral drug discovery and development. During his car
CHICAGO -- Results from an on-going Phase II study showed that antiretroviral suppression was sustained after 48-weeks of treatment with ISENTRESS(TM) (raltegravir), an investigational oral integrase inhibitor, in combination with optimized background therapy (OBT) versus placebo plus OBT in treatment-experienced HIV-i
NEW YORK -- Nearly three times as many patients receiving Selzentry, in addition to an optimized background regimen, achieved undetectable levels of HIV virus compared with those receiving an optimized regimen alone, according to 48 week data presented today in late-breaking sessions at the Interscience Conference on A
NEW YORK -- Pfizer Inc said today that the company plans to present key data on in-line medicines and pipeline research at the Annual Meeting of Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago, Illinois. In addition, Pfizer plans to host an investor meeting on September 18th to revie
SANTA ANA, Calif. -- A star-lit Maasai village marketplace will greet dignitaries and guests of the first annual Safari of Hope (www.safariofhope.org) charity gala. The event, benefiting the African Child Foundation in Kenya , will take place September 22 at the Santa Ana Zoo at Prentice Park in Santa Ana, California.
CHICAGO -- A group of leading drug researchers today announced the formation of a non-profit international institute to channel top talent and drug candidates from the world s leading research labs into a major, new global assault on tuberculosis (TB), malaria, and HIV/AIDS. Founders of the International Drug Discovery
TRENTON, N.J. & MALVERN, Pa. -- The Biotechnology Council of New Jersey (BCNJ) and Pennsylvania Bio announce that Biotech 2007: Imagine. Collaborate. Innovate (www.biotech2007.org), to be held on October 8-9, 2007, at the Loews Philadelphia Hotel, will feature as a keynote speaker Margaret G. McGlynn, R. Ph., presi
CHICAGO -- Nadine Wong, editor of the BioTech Stock Report newsletter, says Gilead (Nasdaq: GILD) is well positioned to remain a leader in new antivirals. Check out her recent comments and learn more about this biotech. Click here for the full story exclusively on Zacks.com: http://at.zacks.com/?id=84 Highlights from t
SAN DIEGO -- AntiCancer, Inc. announced today that it has received patent 7,264,819 on September 4, 2007, entitled Lyase treatment for P. carinii . AntiCancer is currently developing a recombinant bacterial protein drug called PEG-methioninase (methionine lyase) for cancer treatment. This drug is now in late preclinica
CORAL GABLES, Fla. -- The University of Miami School of Nursing and Health Studies has received a $7 million, five year grant from the National Institutes of Health (NIH). These funds will create El Centro, a National Center on Minority Health and Health Disparities (NCMHD) University of Miami Center of Excellence for
ATLANTA -- Inhibitex, Inc. (Nasdaq: INHX) announced today that it has entered into an exclusive worldwide license agreement with the University of Georgia Research Foundation (UGARF) for intellectual property covering a series of HIV integrase inhibitors and other antiviral compounds in exchange for an upfront license
WHITEHOUSE STATION, N.J. -- Merck & Co. , Inc. announced today that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration ( FDA ) voted unanimously to recommend accelerated FDA approval of ISENTRESS(TM) (raltegravir) in combination with other antiretroviral therapy (ART) for the treatment
YONKERS, N.Y. -- Advanced Viral Research Corp. (OTCBB:ADVR), a research based biopharmaceutical company dedicated to anti-cancer drug discovery and development, announced today plans to initiate a Phase II clinical trial to evaluate the effectiveness of its compound AVR118 in the treatment of cachexia-related symptoms
LOS ANGELES -- CytRx Corporation s (NASDAQ:CYTR) majority-owned subsidiary, RXi Pharmaceuticals Corporation (RXi), today announced the grant of an Australian patent issued to the University of Massachusetts Medical School covering in vivo production of small interfering RNA (siRNA) that mediate gene silencing. The gran
LAKE OSWEGO, Ore. -- Calypte Biomedical Corporation (OTCBB: CBMC), medical diagnostic tests manufacturer for the rapid detection of antibodies to the human immunodeficiency virus (HIV), announced today that it has established a branch office in Dubai, United Arab Emirates (UAE) as the Company s regio
SAN DIEGO -- Aethlon Medical, Inc., (OTCBB:AEMD) disclosed today that it has shipped Hemopurifier(R) treatment cartridges to support a clinical study to be conducted at the Fortis Hospital (www.fortishealthcare.com) in Delhi, India . The study, which will evaluate the safety of the Hemopurifier(R) in ten patients, is e
LOS ANGELES -- The Sara Rose Children Foundation, Inc. received a grant from Herbalife Family Foundation s Casa Herbalife program to improve its ability to serve healthier food to children living in its new facility in Kitwe, Zambia . In response to the growing number of orphans and abandoned children affected by the A
STOCKHOLM, Sweden -- Regulatory News: Medivir (STO:MVIRB) has today announced that the licensing rights for MIV-210 have reverted to Medivir from Tibotec Pharmaceuticals Ltd. In previously performed pre-clinical trials, MIV-210 has demonstrated very potent activity against Hepatitis B Virus (HBV) and has good pharmacok
STOCKHOLM, Sweden -- Regulatory News: Medivir AB (STO:MVIRB) has today entered a licensing agreement with the Chinese pharmaceutical company Hainan Noken Pharmaceutical Industry Ltd in relation to the antiviral compound MIV-210. MIV-210 is a polymerase inhibitor and belongs to the group of projects which is administere
MELBOURNE, Australia -- Melbourne-based biotechnology company Avexa Limited (ASX:AVX) announced today positive 24 week data from the phase 2b clinical trial of apricitabine (ATC). The data demonstrate that, in over 80% of patients treated with ATC, the level of HIV in the blood was reduced to below detectable levels af
WATERTOWN, Mass. -- Panacos Pharmaceuticals, Inc. (NASDAQ:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, will present at the 20th Annual Bear Stearns Healthcare Conference to be held from September 10-11 at The Grand Hyatt in New York, NY. Dr. Alan W. Dunto
STOCKHOLM, Sweden -- Regulatory News: A completed share issue of USD 26m in the San Francisco-based company Presidio Pharmaceuticals, Inc., Medivir s (STO:MVIRB) licensing partner for the antiviral compounds alovudine (MIV-310) and PPI-801/802 (MIV-410), will trigger Medivir receiving Series B shares in Presidio. S
TAMPA, Fla. -- The People s Princess Charitable Foundation, Inc. announced today the release of My Decade with Diana - the Perpetual Power of the People s Princess, a heavily illustrated coffee table book, which reveals the story of Princess Diana s heartfelt wish to help the less fortunate by using beautiful things to
SAN FRANCISCO--(BUSINESS WIRE)--Presidio Pharmaceuticals, Inc, a specialty pharmaceutical company focused on developing and commercializing novel, small molecule compounds for the treatment of HIV-1, HCV and other chronic viral infections, announced today that it has closed a $26 million Series B financing led by Panor
LAKE OSWEGO, Ore. -- Calypte Biomedical Corporation (OTCBB: CBMC), a manufacturer of medical diagnostic tests for the rapid detection of antibodies to the human immunodeficiency virus (HIV), announced today its support for the guidance policy unveiled last week by the National AIDS Control Council (NACC) of
MELVILLE, N.Y.--Allion Healthcare, Inc. (NASDAQ: ALLI), a national provider of specialty pharmacy and disease management services focused on HIV/AIDS patients, announced today it will participate in the Thomas Weisel Partners Healthcare Conference 2007 in Boston, Massachusetts at Four Seasons Boston, September 5th thro
DUBLIN, Ireland--Research and Markets (http://www.researchandmarkets.com/reports/c66470) has announced the addition of Infections - AIDS HIV Drug Pipeline Report to their offering. Infections - AIDS HIV Drug Pipeline Report contains detailed information on the current drug pipeline. This report provides insight into th
GAITHERSBURG, Md.--GenVec, Inc. (Nasdaq:GNVC) announced that results from multiple ongoing clinical trials utilizing its adenovector vaccine technologies were presented yesterday at the AIDS Vaccine 2007 Conference taking place in Seattle, Washington this week. The trials, which are investigating a DNA prime- adenovira
SEATTLE--Etubics Corporation, a Seattle-based biopharmaceutical company, has announced that it has received a Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) in the amount of $600,000. The grant will be use
PORTLAND, Ore.--Bioject Medical Technologies Inc. (Nasdaq:BJCT), a leading developer of needle-free drug delivery systems, today reported results from two studies presented at the AIDS Vaccine 2007 Conference in Seattle, Washington, which showed significantly improved results when the Biojector(R)2000 ( B2000 ) needle-
CHARLESTON, S.C.--Gethsemani Circle of Friends, a North Charleston nonprofit organization and the Family Services Research Center at the Medical University of South Carolina (MUSC) are partnering with Nkabom Artist and Craftspeople Association of Accra, Ghana to build a center in Okurase, Ghana that will provide arts-b
SEATTLE--At the AIDS Vaccine 2007 Conference today, Etubics Corporation reported on a novel adenovirus vector vaccine that can boost the HIV/AIDS virus immune response and deliver vaccination against a second disease at the same time. For the first time ever, Etubics has demonstrated that animals can be immunized again
STOCKHOLM, Sweden--Regulatory News: Medivir AB (STO:MVIRB) has succeeded in transferring the licensing agreement on the anti-HIV compound MIV-160 from Guangdong Lantai-Viewland Pharmaceutical Co. Ltd. to Beijing Mefuvir Medicinal Technology Co. Ltd, a subsidiary of one of China s largest condom manufacturers. The compa
SEATTLE & NEW YORK--Amazon.com (NASDAQ:AMZN) and Arista Records, will release on Monday the exclusive, worldwide premiere of the new Annie Lennox video Dark Road on www.amazon.com. For 48 hours, fans around the world will get their first and only look at the new video online at Amazon.com. Dark Road is the first tr
OKLAHOMA CITY--Dr. Ronald Shinn, President and Board of Directors Chairman of ARTEC, Inc. (Pink Sheets:ATKJ), a company in the process of enterprising a revolutionary polysaccharide compound to be used as an HIV/AIDS and ANTI-CANCER immunostimulant, trade named TUBERCINTM, announces key appointments today. The company
MENLO PARK, Calif.--SRI International, an independent nonprofit research and development organization, today announced that it has been awarded a $4.6 million contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to research, develop and manufacture
SAN DIEGO--Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today that its partner, Tripep AB of Sweden , received approvals from the Swedish Medical Products Agency and local ethics committees to initiate a Phase I/II cli
MCLEAN, Va.--BearingPoint, Inc. (NYSE:BE), one of the world s largest management and technology consulting firms, announced that the United States Agency for International Development (USAID) has named BearingPoint as one of six awardees of the AIDS Support and Technical Assistance Resources Contract (AIDSTAR). The con
CHARLOTTE, N.C. -- As part of its commitment to improve worker and patient safety, the Premier Safety Institute this week mailed its new Prevent Needlestick Injuries brochure to Premier members across the continuum of healthcare delivery sites, including surgery centers, home healthcare facilities, imaging centers, cli
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c65222) has announced the addition of Health and Human Rights to their offering. This volume draws together significant articles addressing challenges of applying human rights to promote health in settings ranging from the local to the g
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c65154) has announced the addition of the new Frost & Sullivan Report The Regulatory Environment for Pharmaceutical Products and Medical Devices in Key Sub-Saharan African Countries to their offering. This Frost & Sullivan r
MELBOURNE, Australia -- Avexa Limited (ASX:AVX) announced today its full year financial result for 2007. The Company reported a closing cash balance of $76.9 million and negative operating cash flows for the year of approximately $15.6 million. CEO Dr Julian Chick said, The 2007 financial year saw the Company achieve i
BOCA RATON, Fla. -- Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis (MS) has today announced that its drug development holding, ReceptoPharm, has successfully completed a study of RPI-78. RPI-78 is ReceptoPharm s lead drug candidate being studied for the
DUBLIN, Ireland -- Research and Markets http://www.researchandmarkets.com/reports/c65109 has announced the addition of The Global HIV/AIDS Market Outlook to 2012 to their offering. Some key findings from this report... - The HIV market is forecast to expand at a CAGR of 10.3% over the period 2006-12.
NEW YORK -- Pfizer said today that it now has a total of 47 programs in its Phase II Research and Development pipeline, which is the largest Phase II cohort in its history and represents continued progress toward its target of tripling the company s Phase III portfolio by 2009. The growth of our Phase II cohort is
ALEXANDRIA, Va. -- The Foundation for Hospices in Sub-Saharan Africa, in collaboration with Direct Relief International, is launching a supply chain program to get hospice and palliative care supplies to HIV/AIDS patients in the Eastern Cape of South Africa . This program will bring necessary provisions such as antibio
NEW YORK -- Pfizer Inc announced today that the U.S. Food and Drug Administration ( FDA ) has approved Selzentry(TM) (maraviroc) tablets, the first in a new class of oral HIV medicines in more than 10 years. Selzentry blocks viral entry into white blood cells, significantly reducing viral load and increasing T-cell cou
LYON, France -- Reportlinker.com announces that a new market research report related to the worldwide infectious diseases industry is now available to its catalogue. The Global HIV/AIDS Market Outlook to 2012 http://www.reportlinker.com/p056755/HIV-AIDS-Market.html Some key findings from this report... -- The HIV m
FLEMINGTON, N.J. -- NovaDel Pharma Inc. (AMEX: NVD), today announced that Par Pharmaceuticals has been granted sublicense rights for the development and commercialization of Zensana(TM) (ondansetron HCl, oral spray). Ondansetron is a 5-HT3 antagonist to prevent nausea and vomiting after chemotherapy, radiation and surg
WATERTOWN, Mass. -- Panacos Pharmaceuticals, Inc. (NASDAQ:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced its financial results for the quarter ended June 30, 2007 and reviewed progress in its development programs. Recent Business Highlights:
DURHAM, N.C. -- Constella Group, a leading global provider of professional health services, announced that it has awarded $20,000 to four organizations to improve the lives of orphans living with HIV/AIDS, to reduce stigma and discrimination associated with HIV and sexually transmitted diseases, to promote health and w
WILMINGTON, Del. -- Incyte Corporation (Nasdaq:INCY) today provided a review of the Company s recent progress for its lead drug discovery and development programs in HIV, oncology, diabetes and inflammation and reported second quarter 2007 financial results. Paul A. Friedman, Incyte s President and Chief Executive Offi
BETHLEHEM, Pa. -- OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, today announced the execution of an agreement for the supply of its OraQuick(R) Rapid HIV-1/2 Antibody Test to the Supply Chain Management System ( SCMS ). Created with funds from the President s Emergency Plan for
MELBOURNE, Australia -- Australian biotechnology company Avexa (ASX:AVX) announced today further information relating to its Phase IIb clinical trial on apricitabine (ATC) as presented by Dr Pedro Cahn to the International AIDS Society (IAS) meeting in Sydney yesterday afternoon. Dr Cahn is not only one of Avexa s lead
WASHINGTON -- MRS. BUSH: Thank you all. Thank you, Jerry. Thanks everybody. The promise that I would never have to give a political speech was actually our pre-nup. (Laughter.) But it did -- I also promised that I would run with George, be a jogger with him -- and I never once did it, so I guess I don t feel that bad a
SYDNEY, Australia -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today presented new findings from a phase 1b clinical trial of PRO 140 in individuals infected with the human immunodeficiency virus (HIV), the causative agent of AIDS. At the 4th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatme
WATERTOWN, Mass. -- Panacos Pharmaceuticals, Inc. (NASDAQ: PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced that its programs were the subject of five poster presentations at the fourth International AIDS Society Conference on Pathogenesis, Tr
SYDNEY, Australia -- Results from an ongoing 48 week Phase II study of ISENTRESS(TM) (raltegravir), an investigational oral HIV integrase inhibitor, under development by Merck & Co. , Inc., in combination with tenofovir ( Vi
NEW YORK -- Rates of virologic suppression in patients receiving Pfizer s novel CCR5 antagonist, maraviroc, compared to efavirenz (EFV) were 70.6% vs. 73.1% for less than400 copies/ml and 65.3% vs. 69.3% at less than50 copies/ml in the full analysis set (FAS) study population (n= 360, maraviroc/ n= 361, efavirenz), acc
SAN DIEGO -- Inovio Biomedical Corporation (AMEX:INO), focused on the development of DNA vaccines for cancers and infectious diseases and a novel alternative to surgery to treat localized cancers, announced today its wholly-owned subsidiary, Genetronics, Inc., has entered into separate collaboration agreements with two
SYDNEY, Australia -- Results from a 14-day Phase IIa clinical trial, presented today at the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, demonstrate that INCB9471, an investigational drug for the treatment of HIV-1, the retrovirus that causes the acquired immunodeficiency syn
SYDNEY, Australia -- Gilead Sciences , Inc. (Nasdaq:GILD) today announced the presentation of 144-week data from an ongoing clinical trial, Study 934, comparing a once-daily regimen of Truvada (R) (emtricitabine and tenofovi
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c63496) has announced the addition of Commercial Insight: HIV - Reshaping Treatment Paradigms to their offering. Detailed analysis of the antiretroviral therapy market. 10 year sales forecast for marketed drugs and key pipeline compounds
NEW YORK -- Pfizer Inc announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) issued a positive opinion recommending marketing authorization for Celsentri(R) (maraviroc), the first CCR5 antagonist for use in combination with other antiretroviral agents for
BETHLEHEM, Pa. -- OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, today announced pre-clinical study results for a prototype rapid Hepatitis C ( HCV ) antibody test on the Company s OraQuick(R) test platform, using oral fluid, finger-stick whole blood, venous whole blood, serum an
BALTIMORE -- Profectus BioSciences, Inc., a biotechnology company that develops preventative and therapeutic technologies to reduce the morbidity and mortality caused by viral diseases, today announced the award of an approximately $200,000 Phase 1 Small Business Innovative Research (SBIR) grant from the National Insti
SAN DIEGO -- Aethlon Medical, Inc., (OTCBB:AEMD) announced today that researchers have discovered the Aethlon Hemopurifier(R) is effective in capturing particles that suppress the immune response in cancer patients. The particles, known as exosomes, are released by solid tumors, lymphomas, and leukemia. Exosomes induce
SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD) will host a webcast this afternoon to discuss pre-clinical testing of the Aethlon Hemopurifier(R) as a potential cancer therapy. The webcast will begin at 4:05 pm EDT (1:05 pm PDT) and can be accessed online at: www.aethlonmedical.com/news/cancer.htm. About Aethlon Medica
SAN DIEGO -- Siemens Medical Solutions Diagnostics (www.siemens.com/diagnostics) is showcasing its comprehensive portfolio of performance-driven solutions for the first time at the American Association of Clinical Chemistry (AACC) Conference in San Diego (July 17 - 19, booth #3411)*. This portfolio is a result of bring
ELMSFORD, N.Y. -- BioScrip, Inc. (Nasdaq: BIOS) announced today that UnitedHealthcare, a UnitedHealth Group (NYSE: UNH) company, has awarded BioScrip an agreement to serve as one of two national specialty pharmacy providers of HIV/AIDS and Solid Organ Transplant drugs and services to UnitedHealthcare and its participat
DEERFIELD, Ill. -- Dade Behring Inc. (NASDAQ:DADE) and Roche Diagnostics announced today that they have granted DiaSorin certain rights related to the development, marketing and manufacturing of immunoassays that can be used for the detection of HIV(human immunodeficiency virus)-1 group O. HIV tests are used to screen
TARRYTOWN, N.Y. -- Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) today announced that it has been selected to present results from a phase 1b clinical trial of PRO 140, an investigational drug for the treatment of HIV/AIDS, at the 4th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Preve
SAN FRANCISCO -- Blue Shield of California Foundation (BSCF) today announced grants totaling nearly $11.3 million, including up to $7 million to increase access to health care for uninsured Californians through an initiative that will provide funding to community-based clinics throughout the state. BSCF is also giving
BOCA RATON, Fla. -- Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis (MS) has today announced that its drug development holding, ReceptoPharm, has successfully completed enrollment in its phase IIb human clinical trial for the treatment of Adrenomyeloneur
ARLINGTON, Va. Hyatt Regency Crystal City 10:30 A.M. EDT THE PRESIDENT: Thank you all. Please be seated. Thanks for coming today. In my recent trip down to Central and South America, I told the folks that we were going to host a conference here in Washington, a conference to promote best practices, which really says, h
ARLINGTON, Va. Hyatt Regency Crystal City 1:55 P.M. EDT MRS. BUSH: Thank you all very much. Thanks so much. I m so happy to be with you today at this very important summit. I want to recognize Carlos Gutierrez, the Secretary of the United States -- U.S. Commerce, who is here, Department of Commerce; Dr. Tom Shannon, th
SAN DIEGO -- Aethlon Medical, Inc., (OTCBB:AEMD) a pioneer in developing therapeutic devices for infectious disease, today disclosed that its Hemopurifier(R) treatment technology is the feature of a CNN Pioneers news story. The story can be accessed at: http://www.cnn.com/video/#/video/bestoftv/2007/07/08/ pioneers.blo
WEST LAFAYETTE, Ind. -- Purdue Research Foundation announced Monday (July 9) that it has granted Purdue Research Park startup company Kylin Therapeutics Inc., an exclusive license to commercialize a biotechnology that will better target RNA interference (RNAi) delivery technology to combat disease-causing genes. The li
STOCKHOLM, Sweden -- Regulatory News: Medivir (STO:MVIRB) today announced that Bristol-Myers Squibb (NYSE:BMY) has terminated the development of the preclinical HIV compound MIV-170. The compound did not meet the profile desired by Bristol-Myers Squibb. MIV-170 belongs to the group of polymerase inhibitors that Medivir
MELBOURNE, Australia -- Australian biotechnology company Avexa (ASX:AVX) announced today the completion of apricitabine s controlled, double blinded phase which represents the first 24 week segment of its Phase IIb trial. Patients have now progressed into the open-label section of the trial (weeks 24 to 48) and will co
PALO ALTO, Calif. -- Hercules Technology Growth Capital, Inc. (NASDAQ:HTGC), a leading specialty finance company providing growth capital in the form of venture debt and equity to venture capital and private equity backed technology and life science companies at all stages of development, today announced that on June 2
EMERSON, N.J. -- Energex Systems, Inc. announced today that its experimental therapy known as HemoModulation was effective in reducing viral load and liver inflammation in non-responding Hepatitis C patients. The trial was conducted under an Investigational Device Exemption (IDE) that was granted by the Federal Food an
SAN DIEGO -- Aethlon Medical, Inc., (OTCBB:AEMD) a pioneer in developing therapeutic devices for infectious disease, has scheduled a special webcast event to report on pre-clinical testing of the Aethlon Hemopurifier(R) in cancer therapy. The webcast will begin at 4:05 pm EDT on Tuesday, July 17th. Aethlon CEO, James A
LUSAKA, Zambia - Mututa Memorial Center, Lusaka, Zambia, 1:17 P.M. (Local) MRS. BUSH: Thank you very much, Bruce. Thank you for your very kind introduction, for showing us all the great things that you ve shown us today. I want to recognize Mrs. Maureen Mwanamasa. Thank you very much. Thank you for your hospitality to
LUSAKA, Zambia Regiment Basic School 10:46 A.M. (Local) MRS. BUSH: I want to thank you for coming out today to cover this PlayPump. This is one of the commitments that the United States government made in cooperation with several foundations, as well -- the Case Foundation and the United States -- the PlayPump Foundati
MAPUTO, Mozambique Via Satellite Q -- (in progress) -- President Bush, of course, has called to double funding for AIDS relief in the next five years, to $30 million. That s a move that even impressed his critics, and it can t come too soon: Last year alone, AIDS killed 2.1 million Africans, leaving 12 million orphans.
MAPUTO, Mozambique Via Satellite Q First Lady Laura Bush is on her third trip to Africa, on a mission to fight AIDS and Malaria, and also raise awareness of women s issue. She arrived in Senegal Monday night, then traveled to Mozambique. Later this week she ll visit Zambia and
International News Desks/National Desks MAPUTO, Mozambique -- Via Satellite Q With the United States strong commitment to helping countries in need, First Lady Laura Bush is leading the fight against deadly diseases in Africa. She joins us live from Mozambique, the capital city there, to discuss the differences being m
SAN DIEGO -- Aethlon Medical, Inc., (OTCBB:AEMD) announced today that it has received approval to initiate clinical testing of the Hemopurifier(R) in human studies to be conducted at the Fortis Hospital (www.fortishealthcare.com) in Delhi, India . The study, approved by the Ethics Committee for Research at Fortis Hospi
Investigational Integrase Inhibitor a New Class of Oral HIV Medication WHITEHOUSE STATION, N.J. -- Merck & Co. , Inc. (NYSE: MRK) announced today that the U.S. Food and Drug Administration ( FDA ) has accepted the New Drug Application (NDA) for ISENTRESS(TM) (raltegravir, previously known as MK-0518). Data in the N
DAKAR, Senegal 9:39 A.M. (Local) MRS. BUSH: I thank everyone for coming to Fann Hospital today to see what I ve gotten to see. First, I think it s often overlooked, that one essential thing in the treatment of AIDS, or HIV, is good nutrition. And the gardens that we ve seen here at the Fann Hospital give patients who a
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c60814) has announced the addition of Nigeria Pharmaceuticals & Healthcare Report Q4 2006 to their offering. The Nigeria Pharmaceuticals & Healthcare Report provides independent forecasts and competitive
WOBURN, Mass. -- Nantero, Inc., a nanotechnology company using carbon nanotubes for the development of next-generation semiconductor devices, has provided license rights for biomedical sensors to Alpha Szenszor, Inc., a newly-formed company also based in Woburn, Massachusetts. Alpha Szenszor is developing a suite of se
BETHLEHEM, Pa. -- OraSure Technologies, Inc. (NASDAQ:OSUR) and the National Association of People with AIDS (NAPWA) announced today the launch of the third annual Mayors Campaign Against HIV(TM), a national campaign to encourage testing for HIV and promote the benefits of knowing one s HIV status. The Campaign is being
NORTHAMPTON, Mass. -- The Safe Haven Project announced today the kick off of the Keep the Light Alive II Run/Bike tour. Led by founder and CEO Dave Butler, the 3-day journey to benefit The Safe Haven Project will begin in Albany, New York on Friday, June 29 and end on Sunday, July 1 in Boston Common. Along the way, But
The Magic Johnson Foundation, Inc.: WHO: The Magic Johnson Foundation, Inc. WHAT: The Magic Johnson Foundation, Inc., in partnership with AIDS Healthcare Foundation, Charles R. Drew University, Los Angeles County STD Programs Office and Minority AIDS Project will observe the 13th annual National HIV Testing Day by host
DAKAR, Senegal Aboard Plane 10:21 A.M. EDT MRS. BUSH: Thanks, everyone. I just came out to say hello, and I m glad you re with me. So I think we re going to have a very interesting trip. It s going to be a difficult trip, just because it s so much travel. We re going, obviously, from the west coast to the east coast an
FOSTER CITY, Calif. -- Gilead Sciences , Inc. (Nasdaq:GILD) today announced that Study 103, a Phase III clinical trial evaluating the company s once-daily anti-HIV drug Viread (R) ( tenofovir disoproxil fumarate or tenofovir DF) 300 mg as a potential treatment
Los Angeles County Office of AIDS Programs and Policy: WHAT: Hundreds of Los Angeles County residents are expected to receive FREE, anonymous and confidential HIV testing during HIV Testing Week, held this year from June 25 - June 30 as part of the 13th annual national campaign to encourage voluntary HIV counseling and
NEW YORK -- Pfizer announced today the U.S. Food and Drug Administration ( FDA ) issued an approvable letter for maraviroc, which is under review as a therapy for treatment-experienced patients infected with CCR5-tropic HIV-1. We continue our discussions with the FDA to address outstanding questions and finalize the pr
SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD) disclosed today that it will pursue the commercialization of its 1st generation Hemopurifier(R) in India during the course of the next year. The strategy to initiate commercialization in India corresponds with Aethlon s international objectives and will parallel the compa
GAITHERSBURG, Md. -- GenVec, Inc. (Nasdaq:GNVC), announced today that the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has begun a Phase I clinical trial to test a novel vaccine known as Ad35HIV-EnvA to prevent HIV-1
WATERTOWN, Mass. -- Panacos Pharmaceuticals, Inc. (NASDAQ: PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced preliminary results from the 250 mg cohort of a Phase 2b study of bevirimat (PA-457) in patients failing HIV therapy due to drug resist
WASHINGTON -- The Map Room 7:30 A.M. EDT Q Thanks so much, and thanks to everyone for joining us once again. It certainly is a special treat because I m joined now by First Lady Laura Bush. Thanks so much for your time and thanks so much for agreeing to appear on our show this morning. You certainly have a busy schedul
BALTIMORE -- Profectus BioSciences, Inc., a biotechnology company that develops preventative and therapeutic technologies to reduce the morbidity and mortality caused by viral diseases, today announced the award of an approximately $300,000 Phase 1 Small Business Innovative Research (SBIR) grant from the Division of AI
WASHINGTON -- Howard University Hospital Washington, D.C. MRS. BUSH: Well, I got to meet Dr. Maxwell when she was at the White House on World AIDS Day, where we talked about different programs that were going on in the United States and programs that were going on globally that address AIDS, programs that are funded in
WOODLAND HILLS, Calif. -- Health Benchmarks(R), Inc. (HBI) published a study of more than 2,100 patients diagnosed with HIV who were newly started on a fixed dose combination drug versus its components taken as separate pills. Findings from the study demonstrated that medication adherence was three times greater among
MENLO PARK, Calif. & HONG KONG -- Geron Corporation (Nasdaq: GERN) and the Biotechnology Research Corporation (BRC) of Hong Kong today announced that Geron has increased its stake in their joint venture entity, TA Therapeutics Limited (TAT), from 50% ownership to 75% ownership. TAT is a Hong Kong company that c
NAPA, Calif. -- Medoctor, Inc., has formed a partnership with the World Health Organization (WHO) called Sharing Healthcare Intellectual Property for Development (SHIPD). Other partners are the UK National Health Service and Informa Ltd. WHO announced the partnership at the World Health Assembly in May. The WHO has
WESTLAKE VILLAGE, Calif. -- Dole Food Company, Inc. today announced that it has been awarded the Business Excellence on Tuberculosis Award by the Global Business Coalition on HIV/AIDS for its work to combat the disease in the Philippines . The award was presented Wednesday, June 13 during the 6th Annual GBC Awards for
SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD) announced today that Patent No. 7,226,429 has been issued to Aethlon Medical by the United States Patent and Trademark Office (USPTO). The patent, Method for Removal of Viruses from Blood by Lectin Affinity Hemodialysis, is integral to Aethlon s intellectual property port
Manual Arts High School: WHO: Manual Arts High School students with the support of director Susan Franklin Tanner. WHAT: A collaborative performance piece entitled Choices/Decisiones written and performed by Manual Arts High School students and directed by Susan Tanner. Student participants range in age from 14 to 16 a
BETHLEHEM, Pa. -- OraSure Technologies, Inc. (NASDAQ:OSUR) announced today that it has received approval to affix the CE mark to its OraQuick ADVANCE(R) Rapid HIV-1/2 Antibody Test, which is required to sell this product in the 27 countries that currently make up the European Union. The OraQuick ADVANCE(R) HIV test is
SOFIA, Bulgaria -- Ministry of Health Sofia, Bulgaria 10:15 A.M. (Local) MRS. BUSH: I do want to thank you all for coming to talk about this. The United States government, as you know, has made a very large commitment to target HIV/AIDS, malaria, and tuberculosis in the hardest-hit countries, which, of course, are main
WASHINGTON -- European Union External Relations Commissioner Benita Ferrero-Waldner and German Foreign Minister Frank-Walter Steinmeier today met with the Bulgarian nurses and a Palestinian doctor accused of infecting children with HIV in Libya . I admire the courage of the Bulgarian nurses and the Palestinian doctor,
HEILIGENDAMM, Germany -- The President, In Collaboration With Other Leaders From The G-8 Nations, Took Action To Address A Broad Range Of Global Issues, Including: -- Launching a new global framework to address climate change, energy security, economic growth and sustainable development; -- Committing to partnering
GDANSK, Poland -- Today, Leaders Of Industrialized Nations Discussed Africa At The G-8 Summit In Heiligendamm, Germany . President and Mrs. Bush and other world leaders concluded the three-day G-8 Summit, which was hosted by German Chancellor Merkel.
NEW YORK -- Needham & Company, LLC will hold its Sixth Annual Biotechnology & Medical Technology Conference at the New York Palace Hotel on June 13-14. Over 120 biotechnology and medical technology companies are scheduled to present. Investors at our conference are looking for small, undercovered companies that
HEILIGENDAMM, Germany -- Nine young people presented their recommendations to world leaders at the G8 Summit in Heiligendamm today. The young people - eight from the G8 countries and one from Tanzania -- spent 45 minutes talking to the leaders at the culmination of the week-long J8 Summit, attended by 74 young people f
WASHINGTON -- Provisions in the Patent Reform Act of 2007 (S. 1145) would unintentionally promote uncertainty surrounding - and weaken the enforceability of - validly issued patents, testified a representative of the Biotechnology Industry Organization (BIO) before a congressional committee today. Appearing on behalf o
FOSTER CITY, Calif. -- Gilead Sciences , Inc. (Nasdaq:GILD) today announced that Study 102, a Phase III clinical trial evaluating the company s once-daily anti-HIV drug Viread (R) ( tenofovir disoproxil fumarate or tenofovir DF) 300 mg as a potential treatment
SAN DIEGO -- Inovio Biomedical Corporation (AMEX:INO), focused on the development of DNA vaccines for cancers and infectious diseases and a novel alternative to surgery to treat localized cancers, announced today the company delivered multiple presentations on preclinical study results and new device innovations relati
WATERTOWN, Mass. -- Panacos Pharmaceuticals, Inc. (NASDAQ:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, will present at the Sixth Annual Needham Biotechnology & Medical Technology Conference to be held from June 13-14 at The Palace Hotel in New York, N
EL DORADO HILLS, Calif. -- Dutton Associates continues its coverage of Amarillo Biosciences (OTCBB:AMAR) maintaining a Speculative Buy rating and a price target of $1.90. The 10-page report by Dutton senior analyst Wayne T. Lottinville, CFA is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks,
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c58875) has announced the addition of the new Jain PharmaBiotech report Antiviral Therapeutics - technologies, markets and companies to their offering. This report reviews the current state-of-art of antiviral approaches including va
WAYNE, Pa. & RESEARCH TRIANGLE PARK, N.C. -- MODA Technology Partners (MODA), a software company that provides mobile data acquisition solutions to the pharmaceutical manufacturing industry announced today that Argos Therapeutics has selected MODA-EM(TM) to automate environmental monitoring (EM) processes at their
BETHLEHEM, Pa. -- OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics and the manufacturer of the OraQuick ADVANCE(R) Rapid HIV-1/2 Antibody Test, today issued a statement in support of the recent program announcement by the Centers for Disease Control and Prevention ( CDC ) that it ha
PARIS -- Hemispherx Biopharma, Inc. (AMEX: HEB), a biopharmaceutical company engaged in the clinical development of new drug entities for the treatment of pandemic disease threats, announced today a new scientific report on the activity of its experimental therapeutic Ampligen(R) in combination with approved anti-influ
CLEVELAND -- University Hospitals Case Medical Center (UHCMC) and Case Western Reserve University School of Medicine are part of a nationwide research study to determine the safety and effectiveness of a new smallpox vaccine geared toward adults ages 18 to 34 who have never been vaccinated against the disease. The stud
VIENNA, Switzerland -- Sex icon and adult film mega-star Jenna Jameson demonstrated her international appeal last weekend, strutting the runway for a good cause at the annual Life Ball 2007 in Vienna, Switzerland, marking Europe s largest charity event in the fight against HIV and AIDS. The weekend, highlighted by fash
WASHINGTON, Ronald Reagan Building and International Trade Center -- MRS. BUSH: Thank you, George, for that kind introduction. Thanks to the United States Global Leadership Council for hosting us this morning. Next week, leaders from around the world will gather in Germany to advance goals shared b
BOCA RATON, Fla. -- Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis has today announced that its medical devices division, Designer Diagnostics, has developed a rapid diagnostic test kit for Tuberculosis and will be conducting clinical trials at National
WEST HAVEN, Conn. -- In startling new imagery, a drug developed by NanoViricides, Inc. (Pink Sheets: NNVC) dismantles a virus particle in a visual demonstration of the novel mechanism of action of nanoviricides in vitro. NanoViricides President Dr. Anil Diwan unveiled the electron micrographs at the Nano Science and Te
WASHINGTON, Rose Garden -- THE PRESIDENT: Thank you all for coming. Welcome to the Rose Garden. Today, I m joined by some very determined people who are battling one of the worst epidemics of modern times: the spread of HIV/AIDS. I want to thank you all for being here. I m honored to be in your presence, and I want to
WASHINGTON -- Today, President George W. Bush Announced His Desire To Double America s Commitment to Fight Global HIV/AIDS. He Will Work With Congress To Reauthorize The United States Leadership Against HIV/AIDS, Tuberculosis, And Malaria Act Of 2003, Which Established The President s Emergency Plan For AIDS Relief (PE
MELBOURNE, Australia -- Avexa (ASX:AVX) announced today that it has been awarded an Australian Government Commercial Ready Grant worth $4.3m AUD to develop a new generation of HIV antiviral drugs using fragment based drug design, a non-traditional research methodology. Avexa will work with CSIRO s Molecular and Health
BETHLEHEM, Pa. -- OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Bank of America 2007 Health Care Conference, Four Seasons Hotel in Las Vegas, NV. The conference will be simultaneously webcast over th
WATERTOWN, Mass. -- Panacos Pharmaceuticals, Inc. (NASDAQ:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced the results of a new study indicating that HIV resistant to Protease Inhibitors (PI) may have reduced potential for the development of r
NEW YORK & ATLANTA -- realhealth.TV (www.realhealth.tv), an Internet TV channel dedicated to a new form of consumer health education by showcasing real people sharing their health stories, has teamed with Emory University to provide Internet videos of Emory medical experts dispensing health information and commenta
LOS ANGELES -- Smart SMS Corp. (Pink Sheets:STMC) has partnered with the Africa Foundation For Aids (AFFA) to create a mobile campaign that will allow cell phone users to text in donations. Smart SMS Corp. s VP of Marketing Eric Robinson says, This partnership demonstrates how technology can benefit charities. The abil
HOUSTON -- CytoGenix, Inc. (CYGX.OB) announced today that Dr. Yin Chen, Chief Scientific Officer will present an update on preclinical animal data for DNA vaccines made using the Company s proprietary synDNATM technology at the 2007 DNA Vaccines conference to be held in Malaga, Spain between May 23 and May 25. Dr.
MALAGA, Spain -- VGX Pharmaceuticals novel pandemic influenza vaccine candidates triggered protective immune responses in pre-clinical challenge studies, according to data presented for the first time today at the Third International Conference on DNA Vaccines in Malaga, Spain. VGX scientists created four synthetic con
WATERTOWN, Mass. -- Panacos Pharmaceuticals, Inc. (NASDAQ:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, will present at the Bank of America Health Care Conference to be held from May 30 - June 1, 2007 at The Four Seasons Hotel in Las Vegas, NV. Alan W. Dun
WASHINGTON -- Roche today announced results of a small study demonstrating that all patients who discontinued treatment with Peg-Intron(R) (peginterferon alfa-2b) and ribavirin due to adverse events within the first 12 weeks, were able to complete 12 weeks of treatment with PEGASYS(R) (peginterferon alfa-2a) and ribavi
WASHINGTON -- Results from a new study, presented at the 38th annual Digestive Disease Week (DDW) conference, showed that more than 99 percent of patients with chronic hepatitis C virus (HCV) infection who were treated successfully with PEGASYS(R) (peginterferon alfa-2a) had no detectable virus up to seven years later
SAN DIEGO -- Inovio Biomedical Corp. (AMEX:INO), focused on the development of DNA-based vaccines for cancers and infectious diseases and a novel alternative to surgery to treat localized cancers, announced today that its partner, Tripep AB of Sweden , has provided an update regarding its application to the Swedish Med
N. ANDOVER, Mass. -- Converse continues its long-term partnership with (PRODUCT) RED with a full collection of premium and limited edition footwear for Fall 2007. As the cornerstone of Converse (PRODUCT) RED, the brand will introduce music and culture collaborations with the legendary punk band Ramones, UK band Kaiser
BURLINGTON, N.C. -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE:LH), one of the world s leading clinical laboratories, today announced an agreement to offer a new, highly accurate HIV test for diagnostic use. LabCorp is the first commercial laboratory to enter a supply agreement for Roche Diagnosti
SAN FRANCISCO -- Gilead Sciences , Inc. (Nasdaq:GILD) today announced results of two long-term studies evaluating ambrisentan, an investigational endothelin receptor antagonist (ERA) for the treatment of patients with pulmonary arterial hypertension (PAH). These long-term data are from patients who originally participa
CHARLOTTE, N.C. -- Thousands of children affected by HIV and AIDS will benefit from a new Miracle Recreation Equipment Company playground through the company s donation and teaming with ABC s Extreme Makeover: Home Edition. Camp Heartland, in Carmel, NY, provides an escape for kids affected by HIV and AIDS to be kids a
LOS ANGELES -- Beginning May 21, the Kimberley Locke and Idol Friends Auction, including clothing worn by American Idol finalists from each of the six seasons, will be auctioned off on the Clothes Off Our Back website, with the proceeds going to Camp Heartland and other charities. Camp Heartland is a national non-profi
SAN DIEGO -- Inovio Biomedical Corporation (AMEX:INO), focused on the development of DNA-based vaccines for cancers and infectious diseases and a novel alternative to surgery to treat localized cancers, announced today that partners of the company will present new interim data from two phase I clinical trials of plasmi
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c57185) has announced the addition of Immunology: From Cell Biology to Disease to their offering. Immunology is the area of life science concerned with how an organism fights infection and disease. To defend itself, the body makes use of
LITTLE ELM, Texas -- Retractable Technologies, Inc. (AMEX:RVP), a leading maker of safety needle devices, today reported revenues of $5.8 million for the three months ended March 31, 2007, an increase of 4.5% over the same 2006 period. Unit sales rose 61.5%. These gains were due largely to higher international sales vo
BASEL, Switzerland -- Jain PharmaBiotech has announced the publication of a New Report Antiviral Therapeutics - Technologies, Markets & Companies . This report reviews the current state-of-art of antiviral approaches including vaccines, pharmaceuticals and innovative technologies for delivery of therapeutics. The r
GAITHERSBURG, Md. -- GenVec, Inc. (Nasdaq:GNVC), a biopharmaceutical company developing novel gene-based therapeutic drugs and vaccines, announced today that it was selected for addition to the NASDAQ Biotechnology Index (NBI), effective as of the market open on Monday, May 21, 2007. We are pleased to be included in th
BLUE BELL, Pa. -- VGX Pharmaceuticals Inc. (VGX) announced today that it has signed a license agreement with Baylor College of Medicine (BCM) covering a broad range of Growth Hormone Releasing Hormone ( GHRH ) and related intellectual property for application in humans. Under the terms of the agreement VGX will have ex
MENLO PARK, Calif. -- Geron Corporation (Nasdaq: GERN) today announced that Thomas B. Okarma, Ph.D., M.D., president and chief executive officer, will present an update of the company s product development programs at 2:55 p.m. CEST (8:55 a.m. EDT) on Monday, May 14, 2007, at the Acumen BioFin Rodman & Renshaw 4th
MONTE CARLO, Monaco -- Rodman & Renshaw Global Healthcare Conference 2007 takes place May 14 - 15, 2007 at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco. For in-depth information about the event, visit http://www.rodmanandrenshaw.com/Conferences.asp?CID=conf20. Listed below are Rodman & Renshaw G
NEW YORK -- Standard & Poor s announced today that it has commenced Factual Stock Report coverage on Starpharma Holdings, Ltd. Starpharma Holdings, Ltd. (OTCQX:SPHRY) develops dendrimer nanotechnology for pharmaceutical, life science and other applications. Starpharma is principally composed of two operating compan
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c56488) has announced the addition of Disease and Therapy Review: Neuropathic Pain to their offering. The Neuropathic Pain Disease and Therapy Review provides incidence and prevalence numbers and percentages for major countries, as avail
MELVILLE, N.Y. -- Allion Healthcare, Inc. (NASDAQ: ALLI), a national provider of specialty pharmacy and disease management services focused on HIV/AIDS patients, today announced financial results for the three months ended March 31, 2007. First Quarter 2007 Highlights: * Growth of 42.8% in net sales to $59.0 million.
TARRYTOWN, N.Y. -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its results of operations for the quarter ended March 31, 2007. Revenues for the quarter ended March 31, 2007 totaled $17.6 million compared to revenues of $11.0 million for the same period in 2006. Revenues for the quarter primarily refl
GAITHERSBURG, Md. -- GenVec, Inc. (Nasdaq: GNVC) today announced its financial results for the first quarter ended March 31, 2007. GenVec reported a net loss of $6.0 million ($0.08 per share) compared to a net loss of $4.1 million ($0.06 per share) in the comparable quarter of 2006. The increase in the net loss was pri
BETHLEHEM, Pa. -- OraSure Technologies, Inc. (NASDAQ: OSUR), a market leader in oral fluid diagnostics, today announced record quarterly revenues of $20.1 million for the three months ended March 31, 2007, compared to $15.2 million in revenues recorded for the three months ended March 31, 2006. Increased sales of the C
GAITHERSBURG, Md. -- GenVec, Inc. (Nasdaq:GNVC), today announced that the U.S. Patent and Trademark Office has granted Patent No. 7,214,368 entitled, Therapeutic Regimen For Treating Cancer Comprising the administration Of Adenoviral Vectors Comprising A TNF-a Transgene, and U.S. Patent No. 7,195,896, entitled, Deficie
LAS VEGAS -- here!, America s premium gay television network, is pleased to announce the creation of a national cause-marketing initiative called Change Starts here! The new initiative will support national and local charitable organizations. Charter Members of Change Starts here! are Cable Positive, Aid for AIDS in Ne
SAN DIEGO -- Aethlon Medical, Inc., (OTCBB:AEMD) a pioneer in developing therapeutic devices for infectious disease, disclosed that its Chairman and CEO, James A. Joyce, is scheduled to present at the following conferences during the month of May. May 19th - The San Diego Growth Conference, San Diego, CA. www.californi
LAWRENCEVILLE, N.J. -- Healthcare Providers Direct, Inc., (OTCBB:HPRD) an early-stage company focused on the development and distribution of rapid diagnostic tests directly to physicians offices, announces their partnership with the National Association of Community Health Centers, Inc. (NACHC). HPD is providing 25,000
NEW YORK -- Rx for Africa, Inc. announced today it has merged with Rx Africa ( Ethiopia ) PLC, formerly known as Sunshine Pharmaceutical, and Diamond Entertainment Corporation, a publicly held corporation (OTCBB:DMON) headquartered in Walnut, California. Rx Africa (Ethiopia) PLC owns and operates a state-of-the-art pha
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c55898) has announced the addition of Decisions Resources new report: Updated CDC HIV Testing Guidelines to Shape Evolving Diagnostics Market to their offering. HIV/AIDS stands out as a highly lucrative and expanding market for diagn
WHITEHOUSE STATION, N.J. -- Merck & Co. , Inc. issued the following statement today on the Government of Brazil s decision to issue a compulsory license for STOCRIN(TM) ( efavirenz ): Merck is profoundly disappointed by the decision of the Government of Brazil (GOB) to issue a compulsory license for STOCRIN(TM) (ef
New website increases access to important information on the latest HIV/AIDS research and fundraising opportunities TORONTO--Sapient Canada announced today that it is helping CANFAR, the Canadian Foundation for AIDS Research, raise public awareness of HIV/AIDS and increase its fundraising capacity through improving the
SAN DIEGO -- The Foundation for Hospices in Sub-Saharan Africa (FHSSA) in conjunction with the National Hospice Foundation (NHF) today announced the launch of the Diana Legacy Fund named in honor of Diana, Princess of Wales. The Fund was established to support programs that encourage and sustain hospice and palliative
TARRYTOWN, N.Y.--Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) today announced positive results from the first clinical trial of its investigational drug, PRO 140, in individuals infected with the human immunodeficiency virus (HIV), the causative agent of AIDS. Patients receiving a single 5.0 mg/kg dose of PRO 140 ach
BETHLEHEM, Pa.--OraSure Technologies, Inc. (NASDAQ: OSUR), the market leader in oral fluid diagnostics, announced today that it has been selected by the Malagasy government and its National AIDS Control Program to be the exclusive first-line provider of rapid HIV screening tests for the country s outreach program over
Academy for Educational Development and Johns Hopkins are Partnering with Pfizer to Evaluate the ConnectHIV Initiative NEW YORK--The Pfizer Foundation today announced the names of 20 U.S. community-based AIDS service organizations (ASOs) chosen to participate in ConnectHIV, the Foundation s latest initiative to support
RICHMOND, Va.--Insmed Inc., (Nasdaq:INSM) today announced positive results from a Phase II investigator-sponsored clinical study of the company s drug IPLEX(TM) in HIV-infected patients affected with HIV-associated Adipose Redistribution Syndrome (HARS). Preliminary results from the study, being conducted at the Univer
MALIBU, California--Pepperdine University April 28, 2007 11:22 A.M. PDT MRS. BUSH: Thank you all very, very much. Thank you for this honorary doctorate. I m so happy to be here with all of you. Thank you, Mr. Martin, for your kind introduction. President Benton and Chancellor Runnels, I m honored to receive this degree
FOSTER CITY, Calif. -- The American Society of Human Genetics (ASHG), the Genetics Society of America (GSA) and Applied Biosystems (NYSE:ABI), an Applera Corporation business, are commemorating the fifth annual National DNA Day with activities aimed at reinforcing the value of genetic science education and driving awar
NEW YORK -- Pfizer Inc announced today that the U.S. Food and Drug Administration s ( FDA ) Antiviral Drugs Advisory Committee voted unanimously (12-0) to recommend the approval of maraviroc, a CCR5 antagonist, for use along with other antiretroviral agents for treatment-experienced patients infected with CCR5-tropic H
BLUE BELL, Pa. -- VGX Pharmaceuticals Inc. (VGX) announced today that it has signed a license agreement with the University of Pennsylvania covering novel DNA Vaccines and Therapeutics. Under the terms of the agreement VGX will have exclusive worldwide rights to develop a number of DNA plasmids and constructs with pote
NEW YORK -- realhealth.TV (www.realhealth.tv), an Internet TV channel dedicated to a new form of consumer health education that showcases real people sharing their health stories through online videos, is featuring experts from Johns Hopkins Medicine to provide commentary on health topics affecting real people. While t
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c54750) has announced the addition of Oxford Handbook of Genitourinary Medicine, HIV and AIDS, First Edition to their offering. - Provides a wealth of practical information on sexually transmitted diseases and the principles of providing
VICTORIA, Australia -- Avexa (ASX:AVX) today announced the completion and formalisation of the licensing and collaboration agreement on a CCR5 HIV drug program with TargetDrug of Shanghai on terms as announced on 4 December 2006. Avexa and TargetDrug have already commenced the collaborative phase of the agreement aimed
NEWTON, Mass. -- The Clarks Companies, one of the oldest and most respected shoe companies in the world, underscores its commitment to securing funds for South Africa s AIDS orphans as Soul of Africa celebrates its fourth anniversary. Clarks Soul of Africa philanthropic initiative embraces the concept of sustainable de
BOCA RATON, Fla. -- Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis has today announced that its drug discovery division, ReceptoPharm, has successfully completed initial discussions with Zhong Xin Dong Tai Co., Ltd. (Nanogene Biotechnology) to develop RP
OAKLAND, Calif. -- When it comes to 21st century clothing, one purpose is not enough. Today s consumers want more from their clothes, and the proliferation of dual- and multi-purpose apparel in the marketplace indicates that clothing manufacturers are paying attention. Today, clothing is so much more than the shirt you
WEST HOLLYWOOD, Calif. -- The City of West Hollywood will address the growing crystal methamphetamine (crystal meth) epidemic in Los Angeles County s gay and lesbian communities and unveil part of a new prevention campaign during a news conference on Wednesday, April 11, 2007 at 9:30 a.m. at West Hollywood City Hall, 8
DURHAM, N.C. -- Phase Bioscience, Inc. announced today the appointment of M. Nixon ( Nick ) Ellis, M.B.A., Ph.D. as President and Chief Executive Officer and Member of the Board of Directors. Dr. Gabriel Cipau will take the position of Executive Chairman of the Board. Dr. Ellis is joining our rapidly maturing company a
ATLANTA -- Inhibitex, Inc. (NASDAQ: INHX) announced today that it has entered into a definitive merger agreement with FermaVir Pharmaceuticals, Inc. (OTCBB: FMVR). FermaVir s development-stage antiviral pipeline includes FV-100, a highly potent nucleoside analogue for the treatment of herpes zoster infections ( shingle
OAKLAND, Calif. -- Public Health Service Bureau (PHSB), a leading provider of pharmacy benefit management and information management systems for public health agencies, today announced the launch of its new Document Management Solution specifically designed to support public health entities. By offering a cost effectiv
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c53539) has announced the addition of Human Virology to their offering. -- A concise but comprehensive introduction to virology for medical and dental students. -- Extensively illustrated with many diagrams completely redrawn and upd
BETHLEHEM, Pa. -- OraSure Technologies, Inc. (NASDAQ: OSUR), the market leader in oral fluid diagnostics and the manufacturer of the OraQuick ADVANCE(R) Rapid HIV-1/2 Antibody Test, announced today that it has signed an agreement with Constella Group LLC, to design and develop a telephonic and Internet accessible consu
CLEVELAND -- MemberHealth s CCRx Medicare Part D Prescription Drug Plan is collaborating with beneficiaries who have HIV and their doctors to ensure the beneficiaries take their antiretroviral medicines correctly - every day. Antiretroviral drugs inhibit the replication of HIV and help keep people with HIV healthy. For
BOCA RATON, Fla. -- Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis has announced that it has sponsored the website, stopTBnow.com, to educate the public about Tuberculosis (TB). Many people believe that Tuberculosis was a disease of the past, commented
BOCA RATON, Fla. -- Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis has today announced that its drug discovery division, ReceptoPharm, has received notification of acceptance of its paper for publication in the Critical Reviews in Immunology special con
NUTLEY, N.J. -- Roche today announced the start of a large, multinational trial to examine a new treatment strategy in hepatitis C patients with difficult-to-treat characteristics. This study will evaluate the effect of PEGASYS(R) (peginterferon alfa-2a) and ribavirin in patients who have a high level of genotype 1 vir
WESTPORT, Conn. -- The MetLife Mature Market Institute and the National Alliance for Caregiving, in cooperation with the National Association of Area Agencies on Aging (n4A), have released a publication aimed at making life a little easier for the legions of Americans caring for a sick or disabled friend or relative.
NEW YORK - Enzo Therapeutics, Inc., a wholly owned subsidiary of Enzo Biochem, Inc. (NYSE:ENZ), has treated the first patient in a Phase I/II clinical trial of the company s gene therapy for HIV-1 (Human Immunodeficiency Virus-Type 1) infection. The study, being conducted at UCSF Medical Center, is enrolling HIV-1 infe
WATERTOWN, Mass. -- Panacos Pharmaceuticals, Inc. (NASDAQ: PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced that the Company and the US Food and Drug Administration ( FDA ) have agreed to a revised trial design for the Company s Phase 2b clini
SARASOTA, Fla. - Paul Smith s autographed, multi-colored chair reunites with its collection brethren March 19 at the dkVOGUE Community AIDS Network Benefit - a collaboration between Danish furniture retailer dkVOGUE, Fritz Hansen, State of the Arts Gallery and the Community AIDS Network held at dkVOGUE s Sarasota, FL s
SAN FRANCISCO - The San Francisco Columbarium will display sections of the historic AIDS Memorial Quilt from March 6th-30th, 2007. Along with special guest speaker, human rights activist and creator of the AIDS Quilt, Cleve Jones, The Columbarium will host a Day of Remembrance including a candle lighting and a reading
LOS ANGELES -- Gilead Sciences , Inc. (Nasdaq:GILD) today announced 24-week data from a Phase II clinical trial evaluating three doses of GS 9137 (elvitegravir), a novel oral HIV integrase inhibitor. The data, presented this week at the 14th Conference on Retroviruses and Opportunistic Infections (CROI) by Andrew Zolop
NUTLEY, N.J. & MORRISVILLE, N.C. -- Virtually all patients (98 percent) who received the investigational integrase inhibitor raltegravir, along with FUZEON(R) ( enfuvirtide ) and an active boosted protease inhibitor (darunavir), achieved undetectable levels of HIV (less than 400 copies/mL of blood), according to ne
LOS ANGELES -- Results from two ongoing Phase III studies of ISENTRESS(TM) (raltegravir), an investigational oral integrase inhibitor, demonstrated significantly greater antiretroviral activity of ISENTRESS when used in combination with optimized background therapy (OBT) versus placebo plus OBT in treatment-experienced
PORTLAND, Ore. - AVI BioPharma, Inc. (Nasdaq:AVII - News), presented research results titled Morpholino Antisense Oligomers that Target the Lentiviral Vif Gene and Tar Stem Loop are Novel Antiretroviral Drug Candidates at the 14th Annual Conference on Retroviruses and Opportunistic Infections (CROI), held this week in
BOCA RATON, Fla. -- Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis has today announced that it has partnered with the European Union-based World AIDS Campaign to help raise awareness about global AIDS initiatives aimed at eradicating the disease by 2015
WATERTOWN, Mass. -- Panacos Pharmaceuticals, Inc. (Nasdaq:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced that it has initiated a Phase 1 clinical trial of PA-1050040 (also referred to as PA-040 ), an investigational maturation inhibitor for
AUSTIN, Texas - ResearchPoint, a full-service contract research organization serving the pharmaceutical, biotechnology, and medical device industries, is pleased to announce the recent appointment of Caryll Bentley BSN, MA as Director, Clinical Operations. Ms. Bentley is a proven project leader and brings 18 years of c
FOSTER CITY, Calif. - Gilead Sciences , Inc. (Nasdaq:GILD - News) today announced the completion of a Phase II clinical trial of GS 9137, a novel oral HIV integrase inhibitor. The clinical study met its primary endpoint of non-inferiority in viral load reduction in HIV-positive patients receiving 50 mg or 125 mg of GS
BOCA RATON, Fla. -- Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis has today announced that its Chairman and CEO, Rik J. Deitsch, has been interviewed for the spring biotechnology issue of The Wall Street Transcript. It is an honor to be invited to inte
DAVIS, Calif. - Today Vitalea Science announced it had received a National Institute of Allergy and Infectious Disease (NIAID) grant to develop and test assays to quantify intracellular uptake of the active metabolite of a nucleoside reverse transcriptase inhibitor (NRTI) drug that can be applied to children and neonat
SAN FRANCISCO -- Three years ago Mark Kay, MD, PhD, published the first results showing that a biological phenomenon called RNA interference could be an effective gene therapy technique. Since then he has used RNAi gene therapy to effectively shut down the viruses that cause hepatitis and HIV in mice. With three human
TUKWILA, Wash. - In recognition of National Condom Week, Castle Megastore will sail a balloon of America s Largest Condom, a monster condom the height of a two-story building, tethered on a 120-foot line over its Tukwila store location at 405 Evans Black Drive. The condom will fly through the weekend to remind citizens
WHITEHOUSE STATION, N.J. -- Merck & Co. , Inc. today announced that it has begun to file registrations for ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), a once-daily, single tablet regimen for the treatment of HIV-1 infection in adults, with health authorities in those
LITTLE ELM, Texas - Retractable Technologies, Inc. (AMEX: RVP) announced today that it has been awarded its third major U.S. government contract to provide VanishPoint® safety syringes under the Bush Administration s Global HIV/AIDS initiative (President s Emergency Plan for AIDS Relief). Under the contract, awarded in
WHITEHOUSE STATION, N.J. -- Merck & Co. , Inc.(1), today announced a reduction in the price of its HIV/AIDS medicine, STOCRIN ( efavirenz ), in the least developed countries of the world and those hardest hit by the epidemic. The price of the 600 mg formulation of STOCRIN has been reduced by 14.
NEW YORK -- (OTCBB:CEMI) - Chembio s two FDA-approved rapid HIV tests have been launched in the U.S. market and are available exclusively through Inverness Medical Innovations, Inc. (AMEX: IMA) under the Inverness Clearview(R) brand. Chembio is the exclusive manufacturer of these products. Clearview HIV 1/2 STAT-PAK(R)
STOCKHOLM, Sweden -- Medivir (STO:MVIRB) -- Decision to focus research activities to the Huddinge facility -- Decision on SEK 224.5 m rights issue -- Tibotec filed an application to start clinical trials on the hepatitis C project -- Phase III study on Lipsovir(R) (ME-609) against labial herpes started in July. Just ov
STOCKHOLM, Sweden -- Medivir AB (STO:MVIRB), Sweden, and Guangdong Lantai Viewland Pharmaceutical, China , announced today the signing of a licensing agreement on MIV-160 (MV026048), a non-nucleoside HIV reverse transcriptase inhibitor (NNRTI) in late pre-clinical development. Under the terms of the agreement Guang
BOCA RATON, Fla. -- Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis, has today announced that its drug discovery division, ReceptoPharm, is expanding the clinical research of its lead antiviral drug candidate, RPI-MN, into South America. RPI-MN was used i
MELVILLE, N.Y. -- Allion Healthcare, Inc. (NASDAQ: ALLI), a national provider of specialty pharmacy and disease management services focused on HIV/AIDS patients, today announced the release of an evaluation authored by Joshua Bamberger, M.D., MPH, Medical Director, Housing and Urban Health, San Francisco Department of
LANCASTER, Calif. -- Simulations Plus, Inc. (AMEX:SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, announced that it has released two new powerful predictive models that extend and enhance the capabilities of its class-leading ADMET Predictor software product. A
SANTA CLARA, Calif. & NASHVILLE, Tenn. -- Affymetrix Inc. (Nasdaq:AFFX) and Vanderbilt-Ingram Cancer Center announced today that they have entered into a three-year translational research collaboration to analyze genomic information across a large number of patient samples. Under terms of the agreement, researchers
PURCHASE, N.Y. -- Nutrition 21, Inc. (NASDAQ: NXXI) announced today that daily supplementation with Selenomax(R), the company s high selenium yeast product, suppressed progression of the human immunodeficiency virus (HIV-1) and improved immune cell CD4 counts in HIV-1 seropositive men and women. The benefits reported i
GIG HARBOR, Wash. -- Generic Medical Devices, Inc.(TM) (GMD(TM)), the first company to design, develop, manufacture and supply quality surgical products marketed at generic prices, today announced that the U.S. Food and Drug Administration ( FDA ) has cleared the GMD Universal Circumcision Clamp for market. This marks
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c48803) has announced the addition of the new Changewave Report Antiviral Treatments to their offering. During the week of February 21-24, 2006 we surveyed Alliance healthcare members on trends in Antiviral Treatments for Flu, Hepatitis,
WEST HOLLYWOOD, Calif. -- City of West Hollywood officials reacted swiftly today to news that the Drug Enforcement Administration (DEA) had raided and shut down five medicinal marijuana dispensaries located in West Hollywood. The City of West Hollywood has had a long-standing commitment to the compassionate use of medi
WESTLAKE VILLAGE, Calif. -- Dole Food Company, Inc. today announced that it will strengthen its widely successful Tuberculosis (TB) initiative in 2007 at the company s two Philippine divisions, Dole Packaged Foods-Dolefil and Dole Fresh Fruit-Stanfilco. The program, TB-DOTS, seeks to raise awareness about TB among Dole
SAN FRANCISCO & KING OF PRUSSIA, Pa. -- Presidio Pharmaceuticals, Inc. and Cytokine PharmaSciences, Inc. announced today that Presidio has licensed from Cytokine PharmaSciences the rights to a series of preclinical-stage compounds for treatment of HIV-1 infection. The agreement also includes the Nuclear Exclusion T
A Live and Archived Copy of the Presentation Will Be Available on Incyte s Website on January 8, 2007, Beginning at 8:30 am PT/11:30 am ET WILMINGTON, Del. -- Incyte Corporation (Nasdaq: INCY) will announce today at the 25th Annual JPMorgan Healthcare Conference positive preliminary results from a Phase IIa placebo-con
This information is designed to support, not replace, the relationship that exists between you and your doctor.